文献速递精神分裂症与精神病性障碍心境障碍

米非司酮治疗精神病性抑郁的合并分析:血浆水平与临床反应相关

Combined Analysis of Mifepristone for Psychotic Depression: Plasma Levels Associated With Clinical Response.
PubMed 文献 · Biol Psychiatry · 2018-01-31

该研究合并5项双盲2/3期试验(米非司酮n=833,安慰剂n=627),评估7天米非司酮治疗精神病性抑郁精神病性症状的疗效。结果显示米非司酮显著减少精神病性症状(p<.004),高血浆水平组(≥1637 ng/mL)疗效更显著(p=.0004),需治疗人数分别为7和48。

要点

  • 米非司酮7天治疗精神病性抑郁,合并分析显示显著减少精神病性症状且安全。
  • 高血浆米非司酮水平(≥1637 ng/mL)与安慰剂差异更显著,需治疗人数为7。
  • 高血浆水平最可能通过1200 mg/天剂量达到,不良事件与安慰剂相似。

核心结论

  • 高米非司酮血浆水平与治疗反应关联最强,其次为促肾上腺皮质激素和皮质醇变化。

研究设计与样本

  • 合并5项设计相似的双盲2或3期研究,评估7天米非司酮治疗精神病性抑郁精神病性症状的疗效与安全性,米非司酮n=833,安慰剂n=627。

主要发现

  • 合并结果显示米非司酮减少精神病性症状具有意义疗效(p<.004),安全范围宽。
  • 高血浆水平组(≥1637 ng/mL)较安慰剂疗效更显著(p=.0004)。
  • 高和低米非司酮血浆水平组的需治疗人数分别为7和48。
  • 米非司酮与安慰剂组不良事件相似。

关键数值与推荐

  • 高米非司酮血浆水平定义为≥1637 ng/mL。
  • 高血浆水平组需治疗人数为7,低血浆水平组为48。
  • 治疗血浆水平最可能通过1200 mg/天剂量达到。

临床怎么用

  • 米非司酮可能用于精神病性抑郁的精神病性症状,高血浆水平与更好反应相关。
  • 1200 mg/天剂量最可能达到治疗血浆水平,不良事件与安慰剂相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with psychotic depression exhibit elevated cortisol levels. Competitively antagonizing cortisol at the glucocorticoid receptor with mifepristone demonstrated therapeutic benefit in early studies of patients with psychotic depression. We present a combined analysis of all controlled phase 2 and 3 studies to report antipsychotic differences between treatment with mifepristone or placebo and to evaluate the relative contributions to response of attaining an a priori-defined, high mifepristone plasma level and markers of glucocorticoid receptor antagonism (increases in adrenocorticotropin hormone and cortisol) with treatment. METHODS: Data from five similarly designed double-blind phase 2 or 3 studies evaluating the efficacy and safety of 7-day treatment with mifepristone for the psychotic symptoms of psychotic depression were pooled for analysis (mifepristone n = 833; placebo n = 627). Clinical assessments were performed at baseline and on days 7, 14, 28, 42, and 56. Mifepristone, adrenocorticotropin hormone, and cortisol samples were collected at baseline and day 7. RESULTS: Combined results demonstrated meaningful efficacy (p < .004) for mifepristone in reducing psychotic symptoms with wide safety margins. Patients in the a priori-defined, high mifepristone plasma level group (≥1637 ng/mL) demonstrated a more significant treatment effect over placebo (p = .0004). A number needed to treat of 7 and 48 was observed in the high and low mifepristone plasma level groups, respectively. Adverse events were similar in mifepristone- and placebo-treated patients. CONCLUSIONS: A high mifepristone plasma level carried the strongest association with response, followed by changes in adrenocorticotropin hormone and cortisol. Therapeutic plasma levels of mifepristone were most likely to be achieved with the 1200 mg/day dose.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Block TS, Kushner H, Kalin N, et al. Combined Analysis of Mifepristone for Psychotic Depression: Plasma Levels Associated With Clinical Response. Biol Psychiatry. 2018. PMID: 29523415. doi:10.1016/j.biopsych.2018.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。